title: Ceftiofur attenuates lipopolysaccharide-induced acute lung injury.
abstract: Ceftiofur is a new broad-spectrum, third-generation cephalosporin antibiotic for veterinary use. Our laboratory has previously been reported that ceftiofur can modulate early cytokine responses and increase mouse survival in endotoxemia. In the present study, we investigated the effect of ceftiofur on acute lung injury (ALI) induced by lipopolysaccharide (LPS) in vivo. Mice were pretreated with ceftiofur 1h before challenge with a dose of 0.5mg/kg LPS. Mice treated with LPS alone showed marked increased TNF-alpha, IL-6, and IL-8 levels in the bronchoalveolar lavage fluid (BALF). When pretreated with 30mg/kg of ceftiofur, the TNF-alpha, IL-6, and IL-8 levels were significantly decreased. In addition, the W/D ratio of the lung tissue and the number of total cells, neutrophils and macrophages in the BALF significantly decreased at 8h after pretreatment with ceftiofur. Furthermore, ceftiofur markedly attenuated the LPS-induced histological alteration. These studies indicate that ceftiofur significantly decreases the inflammation in a murine model of LPS-mediated ALI and may represent a novel prevention strategy for nonspecific inflammation in the lungs.
authors.affiliation: Department of Veterinary Pharmacology, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, Jilin 130062, People's Republic of China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Chu
authors.forename: Keji
authors.initials: K
authors.lastname: Song
authors.forename: Kan
authors.initials: K
authors.lastname: Xu
authors.forename: Xiaozhe
authors.initials: X
authors.lastname: Zhang
authors.forename: Xuemei
authors.initials: X
authors.lastname: Zhang
authors.forename: Yu
authors.initials: Y
authors.lastname: Song
authors.forename: Dacheng
authors.initials: D
authors.lastname: Wang
authors.forename: Songcai
authors.initials: S
authors.lastname: Liu
authors.forename: Xuming
authors.initials: X
authors.lastname: Deng
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy* / Q000276:immunology; D000818:Animals; D018893:Bronchoalveolar Lavage; D002452:Cell Count; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects; D016207:Cytokines / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008264:Macrophages / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000187:drug effects* / Q000473:pathology; D011014:Pneumonia / Q000188:drug therapy / Q000276:immunology
chemical_list: D002511:Cephalosporins; D016207:Cytokines; D008070:Lipopolysaccharides; C053503:ceftiofur